olamufloxacin and Respiratory-Tract-Infections

The in vitro activity of HSR-903, an oral quinolone, against 196 recent clinical isolates of respiratory pathogens was evaluated. HSR-903 was 2 to 32 times more active than ofloxacin, ciprofloxacin, and sparfloxacin against Staphylococcus aureus, including methicillin-resistant strains, and Streptococcus pneumoniae and was at least as active as the other quinolones against gram-negative pathogens.

Topics: Anti-Infective Agents; Bacteria; Fluoroquinolones; Microbial Sensitivity Tests; Quinolones; Respiratory Tract Infections

The in vivo activity of HSR-903, a new fluoroquinolone, against major bacteria which cause respiratory tract infections was evaluated. HSR-903 was active against experimental respiratory tract infections in mice challenged with penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae and Haemophilus influenzae strains. Treatment with HSR-903 reduced the bacterial numbers in infected murine lungs. In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae. A pharmacokinetic study with pneumonic mice showed that the levels of HSR-903 in the lungs were seven to eight times higher than those in the plasma. These results indicate that clinical studies of HSR-903 against respiratory tract infections may be warranted.

Topics: Animals; Anti-Infective Agents; Area Under Curve; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Respiratory Tract Infections; Streptococcal Infections; Streptococcus pneumoniae